Agile Therapeutics Balance Sheet - Quarterly (NASDAQ:AGRX)

Add to My Stocks
$0.57 $0.01 (1.72%) AGRX stock closing price Jun 22, 2018 (Closing)

The Agile Therapeutics balance sheet is a snapshot of the company's financial health at a given point of time, whereas the other two financial statements are for a particular accounting period. All three financial statements should be used to measure the financial performance of the company, and should form a part of the Agile Therapeutics stock analysis. Quarterly results announcements include the release of all three financial statements, of which the balance sheet is one. Agile Therapeutics balance sheet as at the end of 2018 Q1 indicates an asset turnover ratio of and debt to equity ratio of . Also check Agile Therapeutics revenue and Agile Therapeutics operating cash flow for the same period.

View and download Agile Therapeutics quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Marketable Securities----------
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets--1.16M-2.52M2.76M3.09M2.07M3.03M3.69M
Total Current Assets
Property Plant & Equipment-14.2M---12.65M---12.62M
Accumulated Depreciation----------
Net Property Plant & Equipment
Investment & Advances----------
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets----------
Total Assets
Notes Payable----------
Accounts Payable2.07M2.78M2.82M2.98M3.18M2.05M2.88M3.01M2.87M2.38M
Current Portion Long-Term Debt----------
Current Portion Capital Leases----------
Accrued Expenses1.13M-1.85M1.18M2.56M3.35M1.75M1.26M1.39M2.65M
Income Taxes Payable----------
Other Current Liabilities9.11M10.63M6.28M6.05M5.84M5.27M3.72M5.84M4.14M2.89M
Total Current Liabilities
Deferred Taxes/Income----------
Convertible Debt----------
Long-Term Debt--5.88M7.88M9.41M10.89M12.07M10M11.47M13.03M
Non-Current Capital Leases----------
Other Long-Term Liabilities----------
Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus259.21M258.09M257.09M237.56M236.59M235.75M234.93M233.98M233.02M194.46M
Retained Earnings-228.6M-221.77M-215.53M-208.42M-200.98M-193.46M-188.26M-180.46M-172.04M-164.72M
Treasury Stock----------
Other Liabilities----------
Shareholders Equity30.6M36.32M41.56M29.14M35.6M42.28M46.66M53.52M60.97M29.74M
Total Liabilities & Shareholders Equity42.92M50.59M58.41M47.25M56.61M63.86M67.11M73.64M80.86M50.71M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The latest Agile Therapeutics stock price, and Agile Therapeutics historical stock prices show the stock price movement over time, and the Agile Therapeutics PE ratio chart displays the PE ratio movement. Apart from stock price, one should also look at balance sheet items which mainly comprise of the following:

  • Assets: An asset is a resource that a corporation like Agile Therapeutics owns and has economic value. The two major types of assets are: fixed assets like real estate, plant and machinery and current assets like cash, marketable securities and inventory. The total asset value for AGRX stock as of 2018 Q1 is $42.92M. Its easy to associate the term with manufacturing companies, which invest a lot in factories and equipment. However, the same cannot be said about tech stocks.
  • Liabilities include short term loans and long term loans availed by the company to fund its business operations. AGRX stock had total liabilities of $12.31M for the quarter 2018 Q1.

Agile Therapeutics Balance Sheet - Key Ratios